anti-pTα-MMAE

anti-pTα-MMAE is an experimental antibody-drug conjugate (ADC) designed for the targeted treatment of T-cell acute lymphoblastic leukemia (T-ALL). It comprises a monoclonal antibody (clone K5G3) that specifically binds to the invariant pTα subunit of the human pre-T cell receptor (pre-TCR), conjugated to the potent microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker. The pre-TCR is a critical developmental checkpoint receptor expressed on leukemia-initiating cells (LICs) in approximately 50% of T-ALL patients but is absent on healthy mature T cells, offering a selective therapeutic window. Upon binding to the pre-TCR, the ADC is rapidly internalized and trafficked to lysosomes, where the linker is cleaved to release MMAE, leading to G2/M cell cycle arrest and apoptosis of the malignant cells. Preclinical studies in patient-derived xenograft (PDX) models have demonstrated that anti-pTα-MMAE significantly inhibits tumor progression and extends survival.

Other names

anti-pTα antibody-drug conjugatepTα-targeted ADC